Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nasopharyngeal Neoplasms | 25 | 2025 | 36 | 8.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2025 | 447 | 2.360 |
Why?
|
| Cisplatin | 11 | 2025 | 139 | 2.170 |
Why?
|
| Chemoradiotherapy | 12 | 2025 | 66 | 2.040 |
Why?
|
| Transient Receptor Potential Channels | 3 | 2022 | 10 | 1.640 |
Why?
|
| Nociception | 3 | 2022 | 10 | 1.600 |
Why?
|
| Induction Chemotherapy | 8 | 2025 | 41 | 1.550 |
Why?
|
| Ion Channels | 2 | 2023 | 89 | 1.400 |
Why?
|
| Drosophila Proteins | 5 | 2023 | 696 | 1.230 |
Why?
|
| Drosophila | 5 | 2023 | 435 | 1.140 |
Why?
|
| Capecitabine | 3 | 2024 | 13 | 1.130 |
Why?
|
| Nociceptors | 3 | 2022 | 9 | 1.010 |
Why?
|
| Paclitaxel | 3 | 2025 | 99 | 0.950 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2025 | 233 | 0.940 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 345 | 0.930 |
Why?
|
| Albumins | 1 | 2024 | 35 | 0.880 |
Why?
|
| Deoxycytidine | 1 | 2024 | 42 | 0.880 |
Why?
|
| Pyridines | 1 | 2024 | 111 | 0.810 |
Why?
|
| Adult Stem Cells | 1 | 2023 | 29 | 0.810 |
Why?
|
| Adenosine | 1 | 2023 | 78 | 0.780 |
Why?
|
| Carcinoma | 7 | 2018 | 122 | 0.780 |
Why?
|
| Axons | 1 | 2023 | 123 | 0.770 |
Why?
|
| Neoplasm Metastasis | 5 | 2024 | 201 | 0.650 |
Why?
|
| Drosophila melanogaster | 3 | 2019 | 498 | 0.630 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 663 | 0.620 |
Why?
|
| Alternative Splicing | 1 | 2019 | 127 | 0.600 |
Why?
|
| Middle Aged | 21 | 2025 | 17553 | 0.540 |
Why?
|
| Adult | 19 | 2025 | 16781 | 0.480 |
Why?
|
| Neoplasm Staging | 6 | 2025 | 501 | 0.480 |
Why?
|
| Male | 21 | 2025 | 29821 | 0.420 |
Why?
|
| Prognosis | 7 | 2024 | 1749 | 0.410 |
Why?
|
| Female | 21 | 2025 | 32791 | 0.390 |
Why?
|
| Nomograms | 3 | 2024 | 18 | 0.390 |
Why?
|
| Aged | 12 | 2025 | 14394 | 0.380 |
Why?
|
| Humans | 29 | 2025 | 63297 | 0.370 |
Why?
|
| Mammals | 2 | 2023 | 217 | 0.360 |
Why?
|
| China | 4 | 2025 | 164 | 0.330 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6630 | 0.330 |
Why?
|
| Animals | 11 | 2023 | 20631 | 0.320 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2020 | 103 | 0.300 |
Why?
|
| Mechanotransduction, Cellular | 2 | 2022 | 27 | 0.290 |
Why?
|
| Vomiting | 3 | 2025 | 137 | 0.290 |
Why?
|
| Protein Isoforms | 2 | 2019 | 197 | 0.270 |
Why?
|
| Fluorouracil | 6 | 2025 | 65 | 0.260 |
Why?
|
| Propensity Score | 2 | 2024 | 156 | 0.250 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2025 | 10 | 0.240 |
Why?
|
| Bone Neoplasms | 1 | 2024 | 126 | 0.200 |
Why?
|
| Retinal Ganglion Cells | 1 | 2023 | 30 | 0.200 |
Why?
|
| Stress, Mechanical | 1 | 2023 | 112 | 0.200 |
Why?
|
| Nerve Regeneration | 1 | 2023 | 36 | 0.200 |
Why?
|
| TRPA1 Cation Channel | 1 | 2022 | 3 | 0.200 |
Why?
|
| Young Adult | 7 | 2025 | 4682 | 0.200 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2020 | 35 | 0.190 |
Why?
|
| Immunotherapy | 1 | 2024 | 255 | 0.190 |
Why?
|
| Organoplatinum Compounds | 2 | 2021 | 21 | 0.190 |
Why?
|
| Transducers | 1 | 2022 | 26 | 0.190 |
Why?
|
| Intestines | 1 | 2023 | 167 | 0.190 |
Why?
|
| Cell Proliferation | 2 | 2023 | 985 | 0.180 |
Why?
|
| SEER Program | 1 | 2021 | 74 | 0.170 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 298 | 0.170 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2020 | 19 | 0.160 |
Why?
|
| Neurofibromin 2 | 1 | 2019 | 3 | 0.160 |
Why?
|
| Integrin beta1 | 1 | 2019 | 32 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 1 | 2019 | 90 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2025 | 88 | 0.150 |
Why?
|
| Carcinogenesis | 2 | 2017 | 130 | 0.150 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 114 | 0.150 |
Why?
|
| RNA, Viral | 1 | 2020 | 276 | 0.150 |
Why?
|
| Chemokine CXCL5 | 1 | 2018 | 7 | 0.150 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2018 | 32 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 524 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 204 | 0.140 |
Why?
|
| Herpesvirus 4, Human | 2 | 2020 | 196 | 0.140 |
Why?
|
| Nasopharynx | 1 | 2017 | 22 | 0.140 |
Why?
|
| NEDD8 Protein | 1 | 2017 | 1 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2021 | 869 | 0.140 |
Why?
|
| Cyclopentanes | 1 | 2017 | 9 | 0.140 |
Why?
|
| Candidiasis | 1 | 2017 | 51 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2024 | 791 | 0.130 |
Why?
|
| Waiting Lists | 1 | 2017 | 50 | 0.130 |
Why?
|
| Pyrimidines | 1 | 2017 | 137 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 111 | 0.120 |
Why?
|
| Neurons | 1 | 2022 | 923 | 0.120 |
Why?
|
| Endemic Diseases | 1 | 2015 | 23 | 0.120 |
Why?
|
| Hydrogen Peroxide | 1 | 2015 | 77 | 0.120 |
Why?
|
| Hepatitis B | 1 | 2015 | 32 | 0.120 |
Why?
|
| Disease-Free Survival | 3 | 2025 | 242 | 0.120 |
Why?
|
| Mice | 4 | 2023 | 10827 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 65 | 0.110 |
Why?
|
| Wnt Proteins | 1 | 2015 | 98 | 0.110 |
Why?
|
| Ultraviolet Rays | 1 | 2015 | 136 | 0.110 |
Why?
|
| Afferent Pathways | 1 | 2014 | 18 | 0.110 |
Why?
|
| Presynaptic Terminals | 1 | 2014 | 37 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 325 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 421 | 0.100 |
Why?
|
| Touch | 1 | 2012 | 27 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 220 | 0.100 |
Why?
|
| Protein Subunits | 1 | 2012 | 166 | 0.100 |
Why?
|
| Apoptosis | 1 | 2017 | 1073 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 424 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2017 | 581 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2025 | 568 | 0.080 |
Why?
|
| Radiotherapy Dosage | 2 | 2021 | 84 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 1465 | 0.070 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2019 | 47 | 0.070 |
Why?
|
| Nausea | 2 | 2018 | 111 | 0.070 |
Why?
|
| Neutropenia | 2 | 2018 | 67 | 0.070 |
Why?
|
| Age Factors | 2 | 2024 | 1559 | 0.060 |
Why?
|
| Cell Movement | 2 | 2019 | 452 | 0.060 |
Why?
|
| Lymphatic Metastasis | 2 | 2017 | 86 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2017 | 273 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 730 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2025 | 200 | 0.060 |
Why?
|
| Adolescent | 4 | 2018 | 6238 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 2458 | 0.060 |
Why?
|
| Signal Transduction | 3 | 2019 | 3033 | 0.050 |
Why?
|
| Sleep Wake Disorders | 1 | 2024 | 72 | 0.050 |
Why?
|
| Survival Rate | 1 | 2025 | 849 | 0.050 |
Why?
|
| Cancer Survivors | 1 | 2024 | 113 | 0.050 |
Why?
|
| Cell Line | 2 | 2019 | 2037 | 0.050 |
Why?
|
| Cyclobutanes | 1 | 2021 | 5 | 0.050 |
Why?
|
| Anxiety | 1 | 2024 | 424 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2017 | 5656 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1377 | 0.040 |
Why?
|
| Immunoprecipitation | 1 | 2019 | 126 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 278 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2019 | 233 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2020 | 224 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2017 | 3285 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 207 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2018 | 9 | 0.040 |
Why?
|
| Taxoids | 1 | 2018 | 26 | 0.040 |
Why?
|
| Anorexia | 1 | 2018 | 7 | 0.040 |
Why?
|
| Hearing Disorders | 1 | 2018 | 10 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2019 | 608 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 67 | 0.040 |
Why?
|
| Depression | 1 | 2024 | 891 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 2571 | 0.030 |
Why?
|
| Gamma Rays | 1 | 2017 | 32 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2018 | 54 | 0.030 |
Why?
|
| Candida | 1 | 2017 | 39 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2019 | 292 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2017 | 64 | 0.030 |
Why?
|
| Time Factors | 1 | 2024 | 3761 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2674 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 190 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2017 | 141 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 174 | 0.030 |
Why?
|
| Aftercare | 1 | 2017 | 76 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 130 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 676 | 0.030 |
Why?
|
| Risk Factors | 2 | 2017 | 5343 | 0.030 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2015 | 6 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 32 | 0.030 |
Why?
|
| Photochemical Processes | 1 | 2015 | 17 | 0.030 |
Why?
|
| RNA Interference | 1 | 2019 | 618 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 205 | 0.030 |
Why?
|
| Wnt-5a Protein | 1 | 2015 | 8 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 63 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 166 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2015 | 232 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2015 | 135 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 935 | 0.030 |
Why?
|
| Topography, Medical | 1 | 2014 | 2 | 0.030 |
Why?
|
| Tripartite Motif Proteins | 1 | 2014 | 42 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 881 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 620 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2020 | 685 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 692 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 701 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 979 | 0.020 |
Why?
|
| Dendrites | 1 | 2012 | 56 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1083 | 0.020 |
Why?
|
| Floxuridine | 1 | 2012 | 5 | 0.020 |
Why?
|
| Larva | 1 | 2012 | 139 | 0.020 |
Why?
|
| Carboplatin | 1 | 2012 | 43 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1121 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 300 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 41 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 863 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2017 | 922 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1649 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 2164 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 1592 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 1990 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 2607 | 0.010 |
Why?
|